Projects per year
BACKGROUND: A SARS-CoV-2+Flu A/B+RSV Combo Rapid test may be more relevant than Rapid Antigen Diagnostic (RAD) tests targeting only SARS-CoV-2 since we are facing a concurrent circulation of these viruses during the winter season.
OBJECTIVES: To assess the clinical performance of a SARS-CoV-2+Flu A/B+RSV Combo test in comparison to a multiplex RT-qPCR.
STUDY DESIGN: Residual nasopharyngeal swabs issued from 178 patients were included. All patients, adults and children, were symptomatic and presented at the emergency department with flu-like symptoms. Characterization of the infectious viral agent was done by RT-qPCR. The viral load was expressed as cycle threshold (Ct). Samples were then tested using the multiplex RAD test Fluorecare ®ฏ SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test. Data analysis was carried out using descriptive statistics.
RESULTS: The sensitivity of the test varies according to the virus, with the highest sensitivity observed for Influenza A (80.8.% [95%CI: 67.2 - 94.4]) and the lowest sensitivity observed for RSV (41.5% [95%CI: 26.2 - 56.8]). Higher sensitivities were observed for samples with high viral loads (Ct < 20) and decrease with low viral loads. The specificity for SARS-CoV-2, RSV and Influenza A and B was >95%.
CONCLUSIONS: The Fluorecare® combo antigenic presents satisfying performance in real-life clinical setting for Influenza A and B in samples with high viral load. This could be useful to allow a rapid (self-)isolation as the transmissibility of these viruses increase with the viral load. According to our results, its use to rule-out SARS-CoV-2 and RSV infection is not sufficient.
|Journal||Journal of Clinical Virology|
|Early online date||28 Feb 2023|
|Publication status||Published - Apr 2023|
FingerprintDive into the research topics of 'Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals'. Together they form a unique fingerprint.
- 2 Active
Clinical Pharmacology Research Group
Douxfils, J., Dogne, J., Musuamba Tshinanu, F., MASEREEL, B., Wieers, G., Haguet, H., RONVAUX, L., Donis, N., Morimont, L., Evrard, J., Siriez, R., Gillot, C., FAVRESSE, J., BOUVY, C., Djokoto, H., Didembourg, M., David, C., Melchionda, S., Maloteau, V., Boucher, A., Devel, P., Modaffari, E., Vandeputte, M., De Messemaeker, A., Decarpentrie, J., Vassart, J. & De Groote, A.
1/04/22 → …
Project: Research Axis
The COVILAB project : Clinical laboratory investigations related to COVID-19
Douxfils, J., Dogne, J., FAVRESSE, J., Tre-Hardy, M., MULLIER, F., Haguet, H., Hardy, M., Melchionda, S., BOUVY, C., Morimont, L., Gillot, C., Djokoto, H., Alpan, L., Devel, P., Modaffari, E. & Maloteau, V.
13/03/20 → …
Data on COVID-19 Detailed by Researchers at University of Namur (Clinical Performance Evaluation of the Fluorecare? Sars-cov-2 & Influenza A/b & Rsv Rapid Antigen Combo Test In Symptomatic Individuals)
1 item of Media coverage
Press/Media: Expert Comment